中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

一种改良诊断量表在急性药物性肝损伤诊断中的应用

仇丽霞 范作鹏 刘颖 梁珊 聂巍 林伟 刘义荣 张晶 胡中杰

引用本文:
Citation:

一种改良诊断量表在急性药物性肝损伤诊断中的应用

DOI: 10.3969/j.issn.1001-5256.2017.07.025
基金项目: 

中国肝炎防治基金会天晴肝病研究基金(TQGB20140052); 中国初级保健基金会佑安肝病艾滋病基金(YNKT20160016); 

详细信息
  • 中图分类号: R575

Application of a modified diagnostic scale in diagnosis of acute drug-induced liver injury

Research funding: 

 

  • 摘要:

    目的建立一种急性药物性肝损伤(DILI)的改良诊断量表并在临床验证使用。方法收集2011年1月-2015年12月在首都医科大学附属北京佑安医院治疗的82例急性DILI患者,其中DILI组52例,非DILI组30例。在Roussel Uclaf因果关系评价表(RUCAM)基础上,参考DDW-J量表,新增"中药单药或成药有肝损伤的报道"、"嗜酸性粒细胞计数"和"基于CCK-8法的药物淋巴细胞刺激试验"3个参数,建立一种改良诊断量表。对2组患者的每种可疑药物分别进行RUCAM和改良诊断量表评分,验证新量表对DILI诊断的敏感度和特异度。计数资料组间比较采用χ2检验。结果 DILI组共75个可疑药物;非DILI组共41个可疑药物。与RUCAM相比,改良诊断量表可将DILI组中评估为"高度可能"和"很可能"的诊断敏感度由74.7%提高至94.7%(χ2=11.554,P=0.001);而非DILI组只有2个药物(4.9%)的评估结果由"可能"变为"很可能",其余药物均维持"可能"、"不太可能"和"可除外",诊断特异度由100%降至95.1%(χ

     

  • [1]FAN ZP, LIANG S, NIE W, et al.The application of a novel drug lymphocyte stimulation test using Cell Counting Kit-8 assay in diagnosis of drug-induced liver injury[J].J Clin Hepatol, 2016, 32 (8) :1562-1565. (in Chinese) 范作鹏, 梁珊, 聂巍, 等.基于细胞计数试剂盒8的药物淋巴细胞刺激试验在急性药物性肝损伤诊断中的应用[J].临床肝胆病杂志, 2016, 32 (8) :1562-1565.
    [2]DANAN G, BENICHOU C.Causality assessment of adverse reactions to drugs---I.A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46 (11) :1323-1330.
    [3]WATANABE M, SHIBUYA A.Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales[J].Hepatol Res, 2004, 30 (3) :148-154.
    [4]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACGClinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.
    [5]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
    [6] HAO KY, YU YC, HE CL.RUCAM sacle-based diagnosis, clinical features and prognosis of 140 cases of drug-induced liver injury[J].Chin J Hepatol, 2014, 22 (12) :938-941. (in Chinese) 郝坤艳, 于乐成, 何长伦.基于Roussel uclaf因果关系评估量表的药物性肝损伤140例诊治分析[J].中华肝脏病杂志, 2014, 22 (12) :938-941.
    [7] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J].Clin Pharmacol Ther, 1981, 30 (2) :239-245.
    [8]MARIA VA, VICTORINO RM.Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis[J].Hepatology, 1997, 26 (3) :664-669.
    [9]TAJIRI K, SHIMIZU Y.Practical guidelines for diagnosis and early management of drug-induced liver injury[J].World J Gastroenterol, 2008, 14 (44) :6774-6785.
    [10]JIANG WH, SHI XH, LIANG WF, et al.Clinical analysis of 124patients with drug-induced hepatitis[J].Chin J Med, 2012, 47 (6) :58-59. (in Chinese) 江文华, 石晓红, 梁伟峰, 等.药物性肝炎124例临床分析[J].中国医刊, 2012, 47 (6) :58-59.
  • 加载中
计量
  • 文章访问数:  2296
  • HTML全文浏览量:  43
  • PDF下载量:  420
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-01-13
  • 出版日期:  2017-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回